Skip to main content
SpringerLink
Log in

Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is a significant cause of morbidity and mortality as well as a public health burden considering the high costs of AF-related hospitalizations. Pre-clinical and clinical evidence showed a potential role of the renin angiotensin system (RAS) in the etiopathogenesis of AF. Among RAS mediators, angiotensin II (AII) and angiotensin 1–7 (A1–7) have been mostly investigated in AF. Specifically, the stimulation of the pathway mediated by AII or the inhibition of the pathway mediated by A1–7 may participate in inducing and sustaining AF. In this review, we summarize the evidence showing that both RAS pathways may balance the onset of AF through different biological mechanisms involving inflammation, epicardial adipose tissue (EAT) accumulation, and electrical cardiac remodeling. EAT is a predictor for AF as it may induce its onset through direct (infiltration of epicardial adipocytes into the underlying atrial myocardium) and indirect (release of inflammatory adipokines, the stimulation of oxidative stress, macrophage phenotype switching, and AF triggers) mechanisms. Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction. Further studies are necessary to prove this benefit in patients with other cardiovascular diseases. Finally, the possibility of using the A1–7 or ACE2 analogues, to enlarge current therapeutic options for AF, may represent an important field of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zoni-Berisso M, Lercari F, Carazza T et al (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 16:213–220

    Google Scholar 

  2. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983–988

    CAS  PubMed  Google Scholar 

  3. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 98:476–484

    CAS  PubMed  Google Scholar 

  4. Benjamin EJ, Wolf PA, D'Agostino RB et al (1998) Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98:946–952

    CAS  PubMed  Google Scholar 

  5. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 158:229–234

    CAS  PubMed  Google Scholar 

  6. Stewart S, Hart CL, Hole DJ, McMurray JJV (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 113:359–364

    PubMed  Google Scholar 

  7. Vidaillet H, Granada JF, Po C et al (2002) A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365–370

    PubMed  Google Scholar 

  8. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ, Casaclang-Verzosa G, Abhayaratna WP, Seward JB, Iwasaka T, Tsang TSM (2007) Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. Eur Heart J 28:1962–1967

    PubMed  Google Scholar 

  9. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF (2006) Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166:719–728

    CAS  PubMed  Google Scholar 

  10. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3:32–38

    PubMed  Google Scholar 

  11. Ringborg A, Nieuwlaat R, Lindgren P, Jonsson B, Fidan D, Maggioni AP, Lopez-Sendon J, Stepinska J, Cokkinos DV, Crijns HJGM (2008) Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace 10:403–411

    PubMed  Google Scholar 

  12. Calkins H, Kuck KH, Cappato R et al (2012) Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 9:632–696.e21

    PubMed  Google Scholar 

  13. Verma A, Macle L, Cox J, Skanes AC, CCS Atrial Fibrillation Guidelines Committee (2011) CCS atrial fibrillation guidelines committee. Canadian cardiovascular society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol 27:60–66

    PubMed  Google Scholar 

  14. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429

    PubMed  Google Scholar 

  15. Stirbys P (2016) Neuro-atriomyodegenerative origin of atrial fibrillation and superimposed conventional risk factors: continued search to configure the genuine etiology of “eternal arrhythmia”. J Atr Fibrillation 9:1503

    PubMed  PubMed Central  Google Scholar 

  16. Nair GM, Nery PB, Redpath CJ et al (2014) The role of renin angiotensin system in atrial fibrillation. J Atrial Fibrillation 6:972

    Google Scholar 

  17. Patel VB, Basu R, Oudit GY (2016) ACE2/Ang 1-7 axis: a critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte 5:306–311

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Wong CX, Ganesan AN, Selvanayagam JB (2017) Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J 38:1294–1302

    CAS  PubMed  Google Scholar 

  19. Rienstra M, McManus DD, Benjamin EJ (2012) Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision-making? Circulation 125:e941–e946

    PubMed  PubMed Central  Google Scholar 

  20. Hatem SN, Sanders P (2014) Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 102:205–213

    CAS  PubMed  Google Scholar 

  21. Kourliouros A, Karastergiou K, Nowell J, Gukop P, Tavakkoli Hosseini M, Valencia O, Mohamed Ali V, Jahangiri M (2011) Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery. Eur J Cardiothorac Surg 39:228–232

    PubMed  Google Scholar 

  22. Smit MD, Maass AH, De Jong AM et al (2012) Role of inflammation in early atrial fibrillation recurrence. Europace 14:810–817

    PubMed  Google Scholar 

  23. Conway DS, Buggins P, Hughes E et al (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148:462–466

    CAS  PubMed  Google Scholar 

  24. Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B (2007) Influence of epicardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol 121:132–134

    PubMed  Google Scholar 

  25. Venteclef N, Guglielmi V, Balse E et al (2015) Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 36:795–805a

    CAS  PubMed  Google Scholar 

  26. Boixel C, Fontaine V, Rucker-Martin C et al (2003) Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 42:336–344

    CAS  PubMed  Google Scholar 

  27. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy P, Bauer JA, van Wagoner D (2001) Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89:E32–E38

    CAS  PubMed  Google Scholar 

  28. Jung UJ, Choi MS (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15:6184–6223

    PubMed  PubMed Central  Google Scholar 

  29. Nagashima K, Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune M, Mano H, Sonoda K, Hiro T, Nikaido M, Hirayama A (2012) Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ Arrhythm Electrophysiol 5:676–683

    PubMed  Google Scholar 

  30. Nakahara S, Hori Y, Kobayashi S, Sakai Y, Taguchi I, Takayanagi K, Nagashima K, Sonoda K, Kogawa R, Sasaki N, Watanabe I, Okumura Y (2014) Epicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: its impact on complex fractionated electrograms and ablation outcome. Heart Rhythm 11:1343–1351

    PubMed  Google Scholar 

  31. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, le Mouroux A, le Métayer P, Clémenty J (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666

    PubMed  Google Scholar 

  32. Romero CA, Orias M, Weir MR (2015) Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol 11:242–252

    CAS  PubMed  Google Scholar 

  33. Mollace V, Gliozzi M, Capuano A, Rossi F (2017) Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers. Int J Cardiol 226:126–131

    PubMed  Google Scholar 

  34. Rossi F, Mascolo A, Mollace V (2017) The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure. Int J Cardiol 226:121–125

    PubMed  Google Scholar 

  35. Borghi C, SIIA Task Force, Rossi F, SIF Task Force (2015) Role of the renin-angiotensin-aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev 22:429–444

    CAS  PubMed  Google Scholar 

  36. Nguyen G (2011) Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 120:169–178

    CAS  Google Scholar 

  37. Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A–9A

    CAS  PubMed  Google Scholar 

  38. Ahmad S, Varagic J, Groban L, Dell’Italia LJ, Nagata S, Kon ND, Ferrario CM (2014) Angiotensin-(1–12): a Chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 16:429

    PubMed  PubMed Central  Google Scholar 

  39. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbrügg HR, Warnecke C, Schaper J, Fleck E, Regitz-Zagrosek V (2001) Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37:1443–1449

    CAS  PubMed  Google Scholar 

  40. Novo G, Guttilla D, Fazio G, Cooper D, Novo S (2008) The role of the renin–angiotensin system in atrial fibrillation and the therapeutic effects of ACE-is and ARBS. Br J Clin Pharmacol 66:345–351

    PubMed  PubMed Central  Google Scholar 

  41. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608–2614

    CAS  PubMed  Google Scholar 

  42. Marchesi C, Paradis P, Schiffrin EL (2008) Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29:367–374

    CAS  PubMed  Google Scholar 

  43. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A (2007) Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 21:20–27

    CAS  PubMed  Google Scholar 

  44. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S (2003) Expression of angiotensin II receptors in human left andright atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42:1785–1792

    CAS  PubMed  Google Scholar 

  45. Zankov DP, Omatsu-Kanbe M, Isono T, Toyoda F, Ding WG, Matsuura H, Horie M (2006) Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in guinea pig atrial myocytes. Circulation 113:1278–1286

    CAS  PubMed  Google Scholar 

  46. Frigolet ME, Torres N, Tovar AR (2013) The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 24:2003–2015

    CAS  PubMed  Google Scholar 

  47. Yvan-Charvet L, Quignard-Boulangé A (2011) Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79:162–168

    CAS  PubMed  Google Scholar 

  48. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MRF, Fazio S, Kon V (2011) Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 31:2856–2864

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Mascolo A, Sessa M, Scavone C, de Angelis A, Vitale C, Berrino L, Rossi F, Rosano G, Capuano A (2017) New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol 227:734–742

    CAS  PubMed  Google Scholar 

  50. Santos RA, Ferreira AJ, Verano-Braga T, Bader M (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and mas: new players of the renin-angiotensin system. J Endocrinol 216:R1–R17

    Google Scholar 

  51. Liu E, Xu Z, Li J, Yang S, Yang W, Li G (2011) Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. Int J Cardiol 146:364–370

    PubMed  Google Scholar 

  52. Liu E, Yang S, Xu Z, Li J, Yang W, Li G (2010) Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. Regul Pept 162:73–78

    CAS  PubMed  Google Scholar 

  53. Souza LL, Costa-Neto CM (2012) Angiotensin-(1–7) decreases LPS-induced inflammatory response in macrophages. J Cell Physiol 227:2117–2122

    CAS  PubMed  Google Scholar 

  54. Zhou T, Han Z, Gu J, Chen S, Fan Y, Zhang H, Yin Y, Zhang J, Wang C (2017) Angiotensin-converting enzyme-2 overexpression improves atrial electrical remodeling through TRPM7 signaling pathway. Oncotarget 8:78726–78733

    PubMed  PubMed Central  Google Scholar 

  55. Patel VB, Mori J, McLean BA et al (2015) ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes 65:85–95

    PubMed  PubMed Central  Google Scholar 

  56. Maisel WH, Stevenson LW (2003) Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D–8D

    PubMed  Google Scholar 

  57. Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J (2014) Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail 7:1042–1049

    PubMed  Google Scholar 

  58. Duca F, Kammerlander AA, Zotter-Tufaro C et al (2016) Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a prospective cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging 9:e005277

    PubMed  Google Scholar 

  59. Shahid F, Lip GYH, Shantsila E (2018) Role of monocytes in heart failure and atrial fibrillation. J Am Heart Assoc 7:e007849

    PubMed  PubMed Central  Google Scholar 

  60. Rutkowska-Zapała M, Suski M, Szatanek R, Lenart M, Węglarczyk K, Olszanecki R, Grodzicki T, Strach M, Gąsowski J, Siedlar M (2015) Human monocyte subsets exhibit divergent angiotensin I-converting activity. Clin Exp Immunol 181:126–132

    PubMed  PubMed Central  Google Scholar 

  61. Yang H, Zeng XJ, Wang HX, Zhang LK, Dong XL, Guo S, du J, Li HH, Tang CS (2011) Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor. Peptides 32:2108–2115

    CAS  PubMed  Google Scholar 

  62. Khatib R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 165:17–24

    PubMed  Google Scholar 

  63. Pedersen OD, Bagger H, Kober L et al (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100:376–380

    CAS  PubMed  Google Scholar 

  64. Hansson L, Lindholm LH, Niskanen L et al (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 20:611–616

    Google Scholar 

  65. Hansson L, Lindholm LH, Ekbom T et al (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 20:1751–1756

    Google Scholar 

  66. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G, GISSI-3 Investigators (2001) GISSI-3 investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86:527–532

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials. Circulation 107:2926–2931

    PubMed  Google Scholar 

  68. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN (2005) Val-HeFT investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548–545

    CAS  PubMed  Google Scholar 

  69. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study. J Am Coll Cardiol 45:712–719

    CAS  PubMed  Google Scholar 

  70. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray J, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, CHARM Investigators (2006) CHARM investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 152:86–92

    PubMed  Google Scholar 

  71. Salehian O, Healey J, Stambler B et al (2007) HOPE investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the heart outcomes prevention evaluation study. Am Heart J 54:448–453

    Google Scholar 

  72. Schmieder RE, Kjeldsen SE, Julius S et al (2008) VALUE trial group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 26:403–411

    CAS  PubMed  Google Scholar 

  73. Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT IV, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ (2012) Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 40:2805–2812

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Verdecchia P, Dagenais G, Healey J et al (2012) Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens 30:1004–1014

    CAS  PubMed  Google Scholar 

  75. McMurray JJ, Packer M, Desai AS et al (2014) PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    PubMed  Google Scholar 

  76. Madrid AH, Bueno MG, Rebollo JM et al (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331–336

    CAS  PubMed  Google Scholar 

  77. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA (2003) Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-lasting persistent atrial fibrillation: results of a prospective and controlled study. Eur Heart J 24:2090–2098

    CAS  PubMed  Google Scholar 

  78. Madrid AH, Marín IM, Cervantes CE et al (2004) Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 5:114–120

    CAS  PubMed  Google Scholar 

  79. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA, AFFIRM Investigators (2004) AFFIRM investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1:669–675

    PubMed  Google Scholar 

  80. Dagres N, Karatasakis G, Panou F, Athanassopoulos G, Maounis T, Tsougos E, Kourea K, Malakos I, Kremastinos DT, Cokkinos DV (2006) Pre-treatment with irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation. Eur Heart J 27:2062–2068

    CAS  PubMed  Google Scholar 

  81. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J (2006) Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 27:1841–1847

    CAS  PubMed  Google Scholar 

  82. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, Rinaldi A (2006) Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 47:46–50

    CAS  PubMed  Google Scholar 

  83. Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, Preti P, Mugellini A (2008) Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 21:1034–1039

    CAS  PubMed  Google Scholar 

  84. Palardy M, Ducharme A, Nattel S, Tardif JC, White M, Racine N, Tétreault K, Dabouz F, Talajic M, Roy D, CTAF Investigators (2008) CTAF investigators. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian trial of atrial fibrillation (CTAF). Can J Cardiol 24:709–713

    PubMed  PubMed Central  Google Scholar 

  85. Disertori M, Latini R, Barlera S et al (2009) GISSI-AF investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617

    PubMed  Google Scholar 

  86. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S (2009) Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53:24–29

    CAS  PubMed  Google Scholar 

  87. Wang JG, Li Y, Shi JH, Han J, Cui YQ, Luo TG, Meng X (2011) Treatment of long-lasting persistent atrial fibrillation using minimally invasive surgery combined with irbesartan. Ann Thorac Surg 91:1183–1189

    PubMed  Google Scholar 

  88. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, on behalf of the J-RHYTHM II Investigators, Katoh T, Igawa O, Matsumoto N, Yamashita T, Kaneko Y, Watanabe E, Ogawa S, Osaka T, Fujii E, Niwano S, Yoshioka K, Kato M, Okazaki O, Kusano K, Okuyama Y, Furushima H, Suzuki M, Noda T, Kawara T, Sato T, Kamakura S, Endoh Y, Kumagai K, Hiyoshi Y, Ishiyama T, Ohtsuka T, Matsumoto M, Chishaki A, Shinohara T, Shirayama T, Koretsune Y, Yokoyama E, Ajiki K, Fujio K, Sugi K, Yamakawa T, Yusu S, Inoue H, Kawamura Y, Hayano M, Date T, Mizusawa Y, Kobayashi Y, Satomi K, Imai Y, Atarashi H, Fukunami M, Yokoshiki H, Betsuyaku T, Okumura K, Takeda H, Matsumoto K, Okishige K, Tagawa M, Hirai M, Okazaki H (2011) J-RHYTHM II investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 13:473–479

    PubMed  Google Scholar 

  89. Yusuf S, Healey JS, Pogue J et al (2011) ACTIVE I investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938

    CAS  PubMed  Google Scholar 

  90. Galzerano D, Di Michele S, Paolisso G et al (2012) A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrialfibrillationrecurrence in hypertensivepatients. J ReninAngiotensin Aldosterone Syst 13:496–503

    Google Scholar 

  91. Fogari R, Mugellini A, Zoppi A, Preti P, Destro M, Lazzari P, Derosa G (2012) Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 17:34–43

    CAS  PubMed  Google Scholar 

  92. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T (2012) Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 5:43–51

    PubMed  Google Scholar 

  93. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ (2000) Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615–620

    CAS  PubMed  Google Scholar 

  94. Pitt B, Segal R, Martinez FA et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 349:747–752

    CAS  PubMed  Google Scholar 

  95. Huang CY, Yang YH, Lin LY, Tsai CT, Hwang JJ, Chen PC, Lin JL (2018) Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. Heart 104:1276–1283

    CAS  PubMed  Google Scholar 

  96. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839

    CAS  PubMed  Google Scholar 

  97. Kalus JS, Coleman CI, White CM (2006) The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 46:21–28

    CAS  PubMed  Google Scholar 

  98. Anand K, Mooss AN, Hee TT, Mohiuddin SM (2006) Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 152:217–222

    CAS  PubMed  Google Scholar 

  99. Khatib R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 165:17–24

    PubMed  Google Scholar 

  100. Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG (2012) Systematic review and meta-analysis: renin-angiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther 26:47–54

    CAS  PubMed  Google Scholar 

  101. Zhao D, Wang ZM, Wang LS (2015) Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res 29:475–485

    PubMed  PubMed Central  Google Scholar 

  102. Chaugai S, Meng WY, Ali SA (2016) Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 21(4):388–404

    CAS  PubMed  Google Scholar 

  103. Saavedra JM (2012) Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 123:567–590

    CAS  Google Scholar 

  104. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K (2000) Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation. 101:2612–2617

    CAS  PubMed  Google Scholar 

  105. Wang X, Li G (2018) Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation. J Renin-Angiotensin-Aldosterone Syst 19:1470320318755269

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Mori Y, Itoh Y, Tajima N (2007) Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens 20:431–436

    CAS  PubMed  Google Scholar 

  107. Iwai M, Horiuchi M (2009) Role of renin-angiotensin system in adipose tissue dysfunction. Hypertens Res 32:425–427

    CAS  PubMed  Google Scholar 

Download references

Funding

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Department of Experimental Medicine, Section of Pharmacology L. Donatelli, University of Campania “Luigi Vanvitelli”, Via Santa Maria di Costantinopoli 16, 80138, Naples, Italy

    Annamaria Mascolo, Konrad Urbanek, Antonella De Angelis, Maurizio Sessa, Cristina Scavone, Liberato Berrino, Annalisa Capuano & Francesco Rossi

  2. IRCCS San Raffaele Pisana, Rome, Italy

    Giuseppe Massimo Claudio Rosano

  3. Cardiovascular and Cell Sciences Research Institute, St. George’s, University of London, London, UK

    Giuseppe Massimo Claudio Rosano

Authors
  1. Annamaria Mascolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Konrad Urbanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonella De Angelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Sessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cristina Scavone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liberato Berrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giuseppe Massimo Claudio Rosano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Annalisa Capuano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Francesco Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annamaria Mascolo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mascolo, A., Urbanek, K., De Angelis, A. et al. Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?. Heart Fail Rev 25, 367–380 (2020). https://doi.org/10.1007/s10741-019-09837-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-019-09837-7

Keywords

Search

Navigation